According to the non-exclusive license agreement, Marina will receive $1m upfront payment.
Marina Biotech president and chief executive officer Michael French said Marina’s CRN is quite versatile and can be used to create stable, highly active oligonucleotide therapeutics and, in particular, both single- and double-stranded oligos.
"We view this license as yet another important validation of our nucleic acid-based drug discovery," French added.
Marina Biotech is a biotechnology company focused on the development and commercialization of oligonucleotide-based therapeutics utilizing multiple mechanisms of action including RNA interference (RNAi) and messenger RNA translational blocking.